Fluconazole-induced Stevens-Jonson syndrome

Keshri, Umashanker Pd; Kumar, Naresh; Kumar, Rajiv; Gari, Manju

doi:10.5455/2319-2003.ijbcp20140629

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AGEP was also described following fluconazole [38,39] and itraconazole administration [40–42]. Severe reactions have been reported with azole drugs such as SJS and TEN following administration of fluconazole [43,44,45 ▪ ,46–49]. In these reported cases, the patients have not received any other medications and, for the majority, they had no history of autoimmune, neoplastic or infectious conditions.…”

Section: Overview Of Antifungal Hypersensitivity Reactionsmentioning

confidence: 99%

Antifungal hypersensitivity reactions and cross-reactivity patterns

Copaescu

Phillips

Trubiano

2021

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewThe goal of this article is to provide an updated understanding and evidence-based approach where possible for antifungal hypersensitivity. This includes recognition of clinical phenotype, implications for cross-reactivity and diagnostic, and management strategy for immediate and delayed hypersensitivity reactions. Recent findingsAntifungal hypersensitivity reactions can be classified according to their latency (immediate or delayed) and clinical phenotype. The majority of the cases described in the literature are delayed T-cell mediated reactions of various severities but immediate reactions consistent with non-Immunoglobulin E (IgE)-mediated mast cell activation and IgE-mediated reactions have also been described. Ancillary information such as skin testing, drug challenge and ex vivo experimental approaches can aid causality assessments and inform antifungal class cross-reactivity, which help optimize antifungal prescribing and stewardship.

show abstract

Section: Overview Of Antifungal Hypersensitivity Reactionsmentioning

confidence: 99%